Zacks Research Has Bearish Estimate for UTHR Q1 Earnings

United Therapeutics Co. (NASDAQ:UTHR) – Analysts at Zacks Research lowered their Q1 2025 EPS estimates for United Therapeutics in a note issued to investors on Monday, March 17th. Zacks Research analyst R. Department now anticipates that the biotechnology company will earn $6.36 per share for the quarter, down from their prior estimate of $6.93. The consensus estimate for United Therapeutics’ current full-year earnings is $24.48 per share. Zacks Research also issued estimates for United Therapeutics’ Q2 2025 earnings at $6.71 EPS, Q3 2025 earnings at $6.95 EPS, Q4 2025 earnings at $6.68 EPS, FY2025 earnings at $26.69 EPS, Q1 2026 earnings at $6.48 EPS, Q2 2026 earnings at $6.76 EPS, Q3 2026 earnings at $7.12 EPS, Q4 2026 earnings at $7.36 EPS, FY2026 earnings at $27.73 EPS and FY2027 earnings at $28.24 EPS.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.10 by $0.09. The business had revenue of $735.90 million during the quarter, compared to the consensus estimate of $734.74 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. During the same quarter last year, the firm earned $4.36 EPS.

UTHR has been the subject of a number of other reports. StockNews.com cut United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, February 27th. HC Wainwright reaffirmed a “buy” rating and issued a $425.00 target price on shares of United Therapeutics in a research report on Thursday, February 27th. Finally, UBS Group lifted their price target on shares of United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a research report on Wednesday, January 8th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat, United Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $388.25.

United Therapeutics Stock Performance

Shares of United Therapeutics stock opened at $318.85 on Wednesday. United Therapeutics has a fifty-two week low of $221.53 and a fifty-two week high of $417.82. The firm has a market capitalization of $14.32 billion, a price-to-earnings ratio of 14.00, a PEG ratio of 0.97 and a beta of 0.64. The stock has a 50 day moving average of $347.20 and a 200 day moving average of $357.65.

Insider Buying and Selling

In other United Therapeutics news, COO Michael Benkowitz sold 10,000 shares of the business’s stock in a transaction on Monday, December 23rd. The shares were sold at an average price of $361.95, for a total value of $3,619,500.00. Following the completion of the transaction, the chief operating officer now owns 2,577 shares in the company, valued at $932,745.15. The trade was a 79.51 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Nilda Mesa sold 255 shares of the company’s stock in a transaction on Monday, December 30th. The stock was sold at an average price of $355.77, for a total value of $90,721.35. Following the sale, the director now directly owns 5,528 shares in the company, valued at $1,966,696.56. This represents a 4.41 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 90,255 shares of company stock valued at $32,614,521 in the last ninety days. Company insiders own 11.90% of the company’s stock.

Institutional Investors Weigh In On United Therapeutics

Hedge funds have recently bought and sold shares of the stock. Thrivent Financial for Lutherans increased its stake in shares of United Therapeutics by 33.7% during the third quarter. Thrivent Financial for Lutherans now owns 14,332 shares of the biotechnology company’s stock worth $5,136,000 after buying an additional 3,615 shares during the period. Quest Partners LLC grew its holdings in United Therapeutics by 347.7% during the 3rd quarter. Quest Partners LLC now owns 1,249 shares of the biotechnology company’s stock worth $448,000 after acquiring an additional 970 shares in the last quarter. Pathstone Holdings LLC increased its position in shares of United Therapeutics by 4.1% in the 3rd quarter. Pathstone Holdings LLC now owns 4,118 shares of the biotechnology company’s stock valued at $1,476,000 after purchasing an additional 163 shares during the last quarter. B. Metzler seel. Sohn & Co. Holding AG acquired a new stake in shares of United Therapeutics in the 3rd quarter valued at $344,000. Finally, PNC Financial Services Group Inc. lifted its position in shares of United Therapeutics by 14.9% during the 3rd quarter. PNC Financial Services Group Inc. now owns 3,179 shares of the biotechnology company’s stock worth $1,139,000 after purchasing an additional 412 shares during the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.